Results 141 to 150 of about 38,144 (289)

Parasomnias and sleep‐related movement disorders induced by drugs in the adult population: a review about iatrogenic medication effects

Journal of Sleep Research, Volume 34, Issue 2, April 2025.
Summary Parasomnias and sleep‐related movement disorders (SRMD) are major causes of sleep disorders and may be drug induced. The objective of this study was to conduct a systematic review of the literature to examine the association between drug use and the occurrence of parasomnias and SRMD.
Sylvain Dumont, Vanessa Bloch, Agnès Lillo‐Lelouet, Christine Le Beller, Pierre A. Geoffroy, Marc Veyrier   +5 more
wiley   +1 more source

Access to Opioid Agonist Treatment during COVID-19 Project

, 2022
Shiv G. Yücel, C. Higgins, Kumar Gupta, Matthew Palm   +3 more
openalex   +2 more sources

Evaluating the feasibility of prolonged-release buprenorphine formulations as an alternative to daily opioid agonist therapy regardless of prior treatment adherence: a pilot study [PDF]

, 2023
Bernadette Hard, Mohan DeSilva
openalex   +1 more source

Reducing stigma within pharmacy opioid agonist treatment encounters.

Stigma and Health
Although community pharmacies are the primary site for opioid agonist treatment (OAT) dispensing in Australia, little is known about the service experiences of consumers and pharmacists. This study aimed to explore how OAT consumers experienced social inclusion and stigma in this setting, and how pharmacists can dispense OAT in ways that minimise ...
openaire   +2 more sources

Comparative Pharmacokinetics of Intranasal or Intramuscular Atipamezole in Unsedated Dogs and Efficacy for Reversal of Xylazine Sedation

Journal of Veterinary Pharmacology and Therapeutics, EarlyView.
ABSTRACT The objectives of this study were to evaluate ATIP pharmacokinetics (PK) in healthy Beagle dogs after IM and IN dosing (Phase I), and to compare the rate of reversal of IM versus IN routes for xylazine (XYL) sedation (Phase II). This study was comprised of two sequential, randomized, crossover experiments. The initial PK study dosed ATIP by IN
Vanessa E. Cowan, Vanessa R. McCrae, Deborah L. Michel, Chloe Lyons, Juliet Kennedy, Yoana C. Reyes Morales, Jennifer M. Loewen, Alan L. Chicoine   +7 more
wiley   +1 more source

Postpartum retention in opioid agonist treatment for opioid dependence: A population-based cohort study. [PDF]

Arch Womens Ment Health
Zhou J, Varney B, Jones N, Bharat C, Degenhardt L, Havard A, Tran DT.   +6 more
europepmc   +1 more source

Examining inequities in access to opioid agonist treatment (OAT) take-home doses (THD): A Canadian OAT guideline synthesis and systematic review

Cayley Russell, Jenna Ashley, Farihah Ali, Nikki Bozinoff, Kim Corace, David C. Marsh, Christopher J. Mushquash, Jennifer Wyman, Maria Zhang, Shannon Lange   +9 more
openalex   +1 more source

Exposure to Subcutaneously Administered Butorphanol in Horses Pre‐Treated With Detomidine or Detomidine‐Vatinoxan

Journal of Veterinary Pharmacology and Therapeutics, EarlyView.
ABSTRACT The aim of the study was to determine the exposure to subcutaneously administered butorphanol in horses pre‐treated with intravenous (IV) detomidine, with or without vatinoxan, a peripherally selective alpha2‐adrenoceptor antagonist. Five healthy, adult horses received three IV treatments 7 days apart, in a randomized, cross‐over design ...
Juhana M. Honkavaara, Ninja P. Karikoski, Laura Palvas, Bruno H. Pypendop, Valtteri M. Rinne, Marja R. Raekallio   +5 more
wiley   +1 more source

Community Pharmacy-Based Injectable Opioid Agonist Treatment: Findings From a Canadian Pilot Program. [PDF]

Drug Alcohol Rev
Mihic T, Socias ME, McCrae K, Johnson C, Nolan S, Grant C, Sutherland C, Fairbairn N.   +7 more
europepmc   +1 more source

People engaged in opioid agonist treatment as a counterpublic during the COVID‐19 pandemic in Australia: A qualitative study

, 2022
Anna Conway, Carla Treloar, Sione Crawford, Jason Grebely, Alison D. Marshall   +4 more
openalex   +1 more source